Cargando…

Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study

BACKGROUND: Patients with atrial fibrillation (AF) are selected for oral anticoagulation based on individual patient characteristics. There is little information on how clinical AF burden associates with the risk of ischaemic stroke or systemic embolism (SSE). The aim of this study was to explore th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaakkola, Samuli, Kiviniemi, Tuomas O., Jaakkola, Jussi, Pouru, Jussi-Pekka, Nuotio, Ilpo, Vasankari, Tuija, Hartikainen, Juha E. K., Airaksinen, K. E. Juhani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132398/
https://www.ncbi.nlm.nih.gov/pubmed/35594342
http://dx.doi.org/10.1080/07853890.2022.2077430
_version_ 1784713370133331968
author Jaakkola, Samuli
Kiviniemi, Tuomas O.
Jaakkola, Jussi
Pouru, Jussi-Pekka
Nuotio, Ilpo
Vasankari, Tuija
Hartikainen, Juha E. K.
Airaksinen, K. E. Juhani
author_facet Jaakkola, Samuli
Kiviniemi, Tuomas O.
Jaakkola, Jussi
Pouru, Jussi-Pekka
Nuotio, Ilpo
Vasankari, Tuija
Hartikainen, Juha E. K.
Airaksinen, K. E. Juhani
author_sort Jaakkola, Samuli
collection PubMed
description BACKGROUND: Patients with atrial fibrillation (AF) are selected for oral anticoagulation based on individual patient characteristics. There is little information on how clinical AF burden associates with the risk of ischaemic stroke or systemic embolism (SSE). The aim of this study was to explore the association of the frequency of cardioversions (CV) as a measure of clinical AF burden on the long-term SSE risk, with a focus on patients at intermediate stroke risk based on CHA(2)DS(2)-VASc score. For these patients, additional SSE risk stratification by assessing CV frequency may aid in the decision on whether to initiate oral anticoagulation. METHODS: This retrospective analysis of FinCV Study from years 2003–2010 included 2074 patients who were not using any oral anticoagulation (long term or temporary) after CVs and undergoing a total of 6534 CVs for AF from emergency departments of three hospitals. Two study groups were formed: high CV frequency (mean interval between CVs ≤12 months and low frequency (>12 months). RESULTS: A total of 107 SSEs occurred during a mean follow-up of 5.4 years. The event rates per 100 patient-years were 1.82 and 0.67 in high versus low CV frequency groups, respectively. After adjustment for CHA(2)DS(2)-VASc score, CV frequency independently predicted SSE (HR, 2.87 [95% CI, 1.47 to 5.64]; p = .002) at 3 years. Competing risk analysis also identified CV frequency (sHR, 2.70 [95% CI, 1.38–5.31]; p = .004) as an independent predictor for SSE. In patients with CHA(2)DS(2)-VASc score 1 and low CV frequency, the SSE risk was only 0.08 per 100 patient-years. CONCLUSIONS: Frequency of CVs for symptomatic AF episodes provides additional information on stroke risk in AF patients with CHA(2)DS(2)-VASc score 1. KEY MESSAGES: This retrospective study offers a unique opportunity to observe the natural course of AF patients with infrequent episodes of clinical arrhythmia when they were not using OAC (before introduction of CHA(2)DS(2)-VASc score). Stroke or systemic embolism rate was very low (0.08 per 100 patient-years) in patients with one CHA(2)DS(2)-VASc point who visited the emergency room for cardioversion less than once a year. Frequency of cardioversions can be used for additional risk stratification in patients at intermediate risk of stroke based on CHA(2)DS(2)-VASc score.
format Online
Article
Text
id pubmed-9132398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91323982022-05-26 Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study Jaakkola, Samuli Kiviniemi, Tuomas O. Jaakkola, Jussi Pouru, Jussi-Pekka Nuotio, Ilpo Vasankari, Tuija Hartikainen, Juha E. K. Airaksinen, K. E. Juhani Ann Med Cardiology & Cardiovascular Disorders BACKGROUND: Patients with atrial fibrillation (AF) are selected for oral anticoagulation based on individual patient characteristics. There is little information on how clinical AF burden associates with the risk of ischaemic stroke or systemic embolism (SSE). The aim of this study was to explore the association of the frequency of cardioversions (CV) as a measure of clinical AF burden on the long-term SSE risk, with a focus on patients at intermediate stroke risk based on CHA(2)DS(2)-VASc score. For these patients, additional SSE risk stratification by assessing CV frequency may aid in the decision on whether to initiate oral anticoagulation. METHODS: This retrospective analysis of FinCV Study from years 2003–2010 included 2074 patients who were not using any oral anticoagulation (long term or temporary) after CVs and undergoing a total of 6534 CVs for AF from emergency departments of three hospitals. Two study groups were formed: high CV frequency (mean interval between CVs ≤12 months and low frequency (>12 months). RESULTS: A total of 107 SSEs occurred during a mean follow-up of 5.4 years. The event rates per 100 patient-years were 1.82 and 0.67 in high versus low CV frequency groups, respectively. After adjustment for CHA(2)DS(2)-VASc score, CV frequency independently predicted SSE (HR, 2.87 [95% CI, 1.47 to 5.64]; p = .002) at 3 years. Competing risk analysis also identified CV frequency (sHR, 2.70 [95% CI, 1.38–5.31]; p = .004) as an independent predictor for SSE. In patients with CHA(2)DS(2)-VASc score 1 and low CV frequency, the SSE risk was only 0.08 per 100 patient-years. CONCLUSIONS: Frequency of CVs for symptomatic AF episodes provides additional information on stroke risk in AF patients with CHA(2)DS(2)-VASc score 1. KEY MESSAGES: This retrospective study offers a unique opportunity to observe the natural course of AF patients with infrequent episodes of clinical arrhythmia when they were not using OAC (before introduction of CHA(2)DS(2)-VASc score). Stroke or systemic embolism rate was very low (0.08 per 100 patient-years) in patients with one CHA(2)DS(2)-VASc point who visited the emergency room for cardioversion less than once a year. Frequency of cardioversions can be used for additional risk stratification in patients at intermediate risk of stroke based on CHA(2)DS(2)-VASc score. Taylor & Francis 2022-05-20 /pmc/articles/PMC9132398/ /pubmed/35594342 http://dx.doi.org/10.1080/07853890.2022.2077430 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cardiology & Cardiovascular Disorders
Jaakkola, Samuli
Kiviniemi, Tuomas O.
Jaakkola, Jussi
Pouru, Jussi-Pekka
Nuotio, Ilpo
Vasankari, Tuija
Hartikainen, Juha E. K.
Airaksinen, K. E. Juhani
Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title_full Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title_fullStr Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title_full_unstemmed Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title_short Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
title_sort frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the fincv-4 study
topic Cardiology & Cardiovascular Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132398/
https://www.ncbi.nlm.nih.gov/pubmed/35594342
http://dx.doi.org/10.1080/07853890.2022.2077430
work_keys_str_mv AT jaakkolasamuli frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT kiviniemituomaso frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT jaakkolajussi frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT pourujussipekka frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT nuotioilpo frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT vasankarituija frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT hartikainenjuhaek frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study
AT airaksinenkejuhani frequencyofcardioversionsasanadditionalriskfactorforstrokeinatrialfibrillationthefincv4study